David Kendall, MD from the International Diabetes Center in Minneapolis, MN discusses recent concerns on diabetes drug safety including TZDs, GLP-1 agonists and long-acting insulin analogs.
Provided by the Institute for Diabetes, Obesity, and Cardiovascular Disease (iDOC), a free resource for continuing medical education and other tools for medical professionals focused on the treatment of these three related conditions. Visit www.idoc.org for more information.
Link to this comment:
All Comments (0)